TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$75 Million

Absci Corporation

Follow-on Offering

Bookrunner, February 2024

Absci Corporation

Absci Corporation (“Absci”) (NASDAQ: ABSI) is a generative AI drug creation company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins. Absci leverages its integrated drug creation platform to identify novel drug targets and create promising biotherapeutic candidates.